Page 23 - scheppingen

GENERAL INTRODUCTION & OUTLINE OF THE THESIS
References
1. WHO. World Health Organization: Epilepsy. WHO Factsheet. 2018.
2. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed
by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy
(IBE). Epilepsia. 2005 Apr;46(4):470-2.
3. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of
epilepsy. Epilepsia. 2014 Apr;55(4):475-82.
4. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International
League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.
Epilepsia. 2017 Apr;58(4):522-30.
5. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia.
2003;44 Suppl 4:21-9.
6. Boshuisen K, van Schooneveld MM, Uiterwaal CS, et al. Intelligence quotient improves after
antiepileptic drug withdrawal following pediatric epilepsy surgery. Annals of neurology. 2015
Jul;78(1):104-14.
7. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet neurology. 2012
Sep;11(9):792-802.
8. Kwan P, Brodie MJ. Early identification of refractory epilepsy. The New England journal of medi-
cine. 2000 Feb 3;342(5):314-9.
9. Sisodiya SM. Mechanisms of antiepileptic drug resistance. Current opinion in neurology. 2003
Apr;16(2):197-201.
10. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal
by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010
Jun;51(6):1069-77.
11. Shallcross AJ, Becker DA, Singh A, et al. Illness perceptions mediate the relationship between
depression and quality of life in patients with epilepsy. Epilepsia. 2015 Nov;56(11):e186-90.
12. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe.
European journal of neurology. 2005 Jun;12 Suppl 1:1-27.
13. Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P. Estimating the cost of epilepsy in Europe: a
review with economic modeling. Epilepsia. 2007 Dec;48(12):2224-33.
14. Boon P, De Cock E, Mertens A, Trinka E. Neurostimulation for drug-resistant epilepsy: a system-
atic review of clinical evidence for efficacy, safety, contraindications and predictors for response.
Current opinion in neurology. 2018 Apr;31(2):198-210.
15. Schulze-Bonhage A. Brain stimulation as a neuromodulatory epilepsy therapy. Seizure. 2017
Jan;44:169-75.
16. Ben-Menachem E. Neurostimulation-past, present, and beyond. Epilepsy currents. 2012
Sep;12(5):188-91.
17. Wiebe S, Blume WT, Girvin JP, Eliasziw M, Effectiveness, Efficiency of Surgery for Temporal Lobe
Epilepsy Study G. A randomized, controlled trial of surgery for temporal-lobe epilepsy. The New
England journal of medicine. 2001 Aug 2;345(5):311-8.
18. Stevelink R, Sanders MW, Tuinman MP, et al. Epilepsy surgery for patients with genetic refractory
epilepsy: a systematic review. Epileptic disorders : international epilepsy journal with videotape.
2018 Apr 1;20(2):99-115.
19. Braun KPJ, Cross JH. Pediatric epilepsy surgery: the earlier the better. Expert review of neurother-
apeutics. 2018 Apr;18(4):261-3.
20. Blumcke I, Spreafico R, Haaker G, et al. Histopathological Findings in Brain Tissue Obtained during
Epilepsy Surgery. The New England journal of medicine. 2017 Oct 26;377(17):1648-56.
21. Martin K, Jackson CF, Levy RG, Cooper PN. Ketogenic diet and other dietary treatments for epi-
lepsy. The Cochrane database of systematic reviews. 2016 Feb 9;2:CD001903.
22. Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: a review of neurological
aspects. European Journal of Paediatric Neurology. 2002;6(1):15-23.
23. Bolton PF. Neuroepileptic correlates of autistic symptomatology in tuberous sclerosis. Mental
Retardation & Developmental Disabilities Research Reviews. 2004;10(2):126-31.
24. Connolly MB, Hendson G, Steinbok P. Tuberous sclerosis complex: a review of the management of
21
one